Last data update: Mar 10, 2025 . (Total: 48852 publications since 2009 )
Incidence of leading causes of pediatric chronic kidney disease using electronic health record-driven computable phenotype
Beus JM , Liu K , Westbrook A , Harding JL , Orenstein EW , Shin HS , Kandaswamy S , Wekon-Kemeni C , Pavkov ME , Xu F , Smith EA , Rouster-Stevens KA , Prahalad S , Greenbaum LA , Wang CS . Kidney360 2025 ![]() BACKGROUND: Incidence data on pediatric chronic kidney disease (CKD) is incomplete. We developed electronic health record (EHR)-based algorithms (e-phenotypes) to identify cases and provide incidence estimates of 5 leading causes of pediatric CKD. METHODS: E-Phenotypes using common standardized clinical terminology were built and contained utilization, diagnostic, procedural, age, and time-period inclusion and exclusion criteria for autosomal dominant polycystic kidney disease (ADPKD), Alport Syndrome (AS), congenital anomalies of the kidney and urinary tract (CAKUT), lupus nephritis (LN), and primary childhood nephrotic syndrome (NS). Cases diagnosed between 2014 and 2023 were identified from a pediatric healthcare system that is the sole pediatric nephrology provider serving the Atlanta Metropolitan Statistical Area (MSA). The performance of the e-phenotypes was tested using a cohort of 1,000 pediatric patients. Cases identified were used to estimate incidences using population information from the Georgia Department of Health. RESULTS: The e-phenotypes demonstrated sensitivity ranging from 0.83 to 0.95, specificity 0.96 to 1.00, PPV 0.81 to 1.00, and NPV 0.98 to 1.00. All positive likelihood ratios (LR) were >20 and negative LR < 0.20. The 6,814 combined cases of ADPKD (n=107), AS (n=31), CAKUT (n=6,120), LN (n=161), and NS (n=395) had an annual incidence of 47.07 (95% CI 45.96-48.20) per 100,000 children. Annual incidence per 100,000 children (95% CI) for each condition was: ADPKD 0.74 (0.61- 0.89), AS 0.21 (0.15-0.30), CAKUT 42.28 (41.22-43.35), LN 1.11 (0.95-1.30), and NS 2.73 (2.47-3.01). CONCLUSIONS: Our incidence estimates suggest CKD conditions are common among children. The e-phenotypes require validation for use at other institutions but offer opportunities to examine determinants of CKD detection, management, and outcomes. |
Breaking barriers: CDC and American Diabetes Association unite to combat diabetes
Holliday CS , Gabbay RA . Prev Chronic Dis 2025 22 E08 ![]() |
Cardiovascular disease lipids and lipoproteins biomarker standardization
Lyle AN , Danilenko U , Sugahara O , Vesper HW . Crit Rev Clin Lab Sci 2025 1-22 ![]() Cardiovascular disease (CVD) is the leading cause of mortality in the United States and globally. This review describes changes in CVD lipid and lipoprotein biomarker measurements that occurred in line with the evolution of clinical practice guidelines for CVD risk assessment and treatment. It also discusses the level of comparability of these biomarker measurements in clinical practice. Comparable and reliable measurements are achieved through assay standardization, which not only depends on correct test calibration but also on factors such as analytical sensitivity, selectivity, susceptibility to factors that can affect the analytical measurement process, and the stability of the test system over time. The current status of standardization for traditional and newer CVD biomarkers is discussed, as are approaches to setting and achieving standardization goals for low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), triglycerides (TG), lipoprotein(a) (Lp(a)), apolipoproteins (apo) A-I and B, and non-HDL-C. Appropriate levels of standardization for blood lipids are maintained by the Centers for Disease Control and Prevention's (CDC) CVD Biomarkers Standardization Program (CDC CVD BSP) using the analytical performance goals recommended by the National Cholesterol Education Program. The level of measurement agreement that can be achieved is dependent on the characteristics of the analytes and differences in measurement principles between reference measurement procedures and clinical assays. The technical and analytical limitations observed with traditional blood lipids are not observed with apolipoproteins. Additionally, apoB and Lp(a) may more accurately capture CVD risk and residual CVD risk, respectively, than traditional lipids, thus prompting current guidelines to recommend apolipoprotein measurements. This review further discusses CDC's approach to standardization and describes the analytical performance of traditional blood lipids and apoA-I and B observed over the past 11 years. The reference systems for apoA-I and B, previously maintained by a single laboratory, no longer exist, thus requiring the creation of new systems, which is currently underway. This situation emphasizes the importance of a collaborative network of laboratories, such as CDC's Cholesterol Reference Methods Laboratory Network (CRMLN), to ensure standardization sustainability. CDC is supporting the International Federation of Clinical Chemistry and Laboratory Medicine's (IFCC) work to establish such a network for lipoproteins. Ensuring comparability and reliability of CVD biomarker measurements through standardization remains critical for the effective implementation of clinical practice guidelines and for improving patient care. Utilizing experience gained over three decades, CDC CVD BSP will continue to improve the standardization of traditional and emerging CVD biomarkers together with stakeholders. |
Social vulnerability and the prevalence of autism spectrum disorder among 8-year-old children, Autism and Developmental Disabilities Monitoring Network, 2020
Patrick ME , Williams AR , Shaw KA , Durkin M , Hall-Lande J , Vehorn A , Hughes M . Ann Epidemiol 2025 104 8-14 ![]() PURPOSE: The Autism and Developmental Disabilities Monitoring (ADDM) Network estimates the prevalence of autism spectrum disorder (ASD) throughout the United States. Reports through 2010 found higher prevalence in areas of higher socioeconomic status. Reports since 2018 indicate a pattern change. We used CDC's Social Vulnerability Index (SVI) to examine the association of ASD prevalence and social vulnerability in ADDM Network sites. METHODS: Cases of ASD among 8-year-old children in 2020 were linked to SVI measures and population estimates. Tracts were categorized into tertiles (high, medium, and low) and prevalence, prevalence ratios (PRs), and 95 % confidence intervals (CIs) were calculated. RESULTS: Among 5998 children with ASD, we saw higher ASD prevalence in areas with high versus low vulnerability overall (26.18 per 1000; PR=1.06 (1.00-1.13)) and in areas with more minority residents (28.28 per 1000; PR=1.29 (1.21-1.38)), less transportation (27.32 per 1000; PR=1.13 (1.06-1.20)), and greater disability (26.83 per 1000; PR=1.09 (1.02-1.17)). This pattern was observed among White children (PR=1.48 {1.36-1.60}) but reversed among Black (PR=0.61 {0.53-0.70}), Asian (PR=0.58 {0.46-0.73}), and Hispanic (PR=0.83 {0.72-0.95}) children. CONCLUSIONS: Disparities in prevalence of ASD by neighborhood-level social vulnerability persist. Directing resources toward providing equitable access to healthcare and support services could help close this gap. |
Association of HFE genotypes with hemochromatosis-related phenotypes in the All of Us research program
Rao ND , Moonesinghe R , Shi L , Adams PC , Jarvik GP , Kowdley KV , Schieve LA , Grosse SD , Dotson WD , Khoury MJ . Genet Med Open 2025 3 101959 ![]() ![]() PURPOSE: Type 1 hereditary hemochromatosis (HH) can result in iron overload and liver disease if not detected and treated early. Most cases are found among people homozygous for HFE p.Cys282Tyr variants. Compound heterozygosity with the HFE p.His63Asp variant is associated with disease to a lesser degree. We sought to examine the association of HFE variation with HH-related phenotypes and assess the prevalence of testing and diagnosis of HH using All of Us data. METHODS: We used data from 133,978 participants with genetic information linked to medical records. For different HFE genotypes, we examined the prevalence of HH diagnosis codes and related biochemical and clinical phenotypes. RESULTS: Among participants who were p.Cys282Tyr homozygotes, the prevalence of HH diagnosis codes was 22.6% among males and 15.6% among females. Serum transferrin-iron saturation measures were available only for 31.4% of males and 21.1% of females who were p.Cys282Tyr homozygotes. Liver disease, including cirrhosis or hepatocellular carcinoma, was present more among males who were p.Cys282Tyr homozygotes compared with males with no p.Cys282Tyr or p.His63Asp variants (15.5% vs 8.5%, P = .0001). Of the 71 participants who were p.Cys282Tyr homozygotes with indication of liver disease, 32 (45.1%) did not have a serum transferrin-iron saturation measure, and 37 (52.1%) did not have diagnosis codes for HH. CONCLUSION: Limited serum transferrin-iron saturation measures or HH diagnosis codes among p.Cys282Tyr homozygotes, even those with liver disease, suggests potential undertesting and underdiagnosis of type 1 HH in clinical practice and a need for improved awareness, education, and testing around HH. |
Invasive group B streptococcal disease among non-pregnant adults - Alaska, 2004-2023
Balta VA , Bressler S , Massay S , Orell L , Reasonover A , Harker-Jones M , Kretz T , Fischer M , McLaughlin J , Steinberg J . J Infect Dis 2025 ![]() ![]() ![]() We describe the epidemiology of invasive group B streptococcal (GBS) disease among non-pregnant Alaska adults using statewide surveillance data. During 2004-2023, 880 cases of invasive GBS disease were reported for an age-adjusted annual incidence of 9.1 (95% CI, 8.5-9.7) cases per 100,000 adults. Incidence increased 1.9-fold (95% CI, 1.6-2.2) between 2004-2013 and 2014-2023. Adults aged ≥65 years had a 4.4-fold higher risk of invasive disease compared to younger adults, and 47% of adults with invasive GBS had diabetes. Healthcare providers should be aware of populations at increased risk, potentially allowing for more prompt treatment. |
Molecular evolution and epidemiology of norovirus GII.4 viruses in the United States
Barclay L , Montmayeur AM , Cannon JL , Mallory ML , Reyes YI , Wall H , Baric RS , Lindesmith LC , Vinjé J , Chhabra P . J Infect Dis 2025 ![]() ![]() ![]() BACKGROUND: Noroviruses are the leading cause of acute gastroenteritis worldwide with GII.4 Sydney viruses responsible for the majority of infections until 2023. METHODS: To study the evolutionary dynamics of GII.4 noroviruses in the US (2011-2023), we sequenced and analyzed 406 VP1 and 335 RdRp sequences submitted to CaliciNet. RESULTS: Time-scale analysis showed the average evolutionary rate of GII.4 strains was 5.56 x 10-3 substitutions/site/year and the emergence of a new cluster within GII.4 Sydney every 4 years starting with GII.4 Sydney[P31] from 2011-2015 followed by GII.4 Sydney[P16] from 2016-2020, and the most recent GII.4 Sydney[P16]-2020 from 2021-to date. Since 2017, based on amino acids in VP1, we observed the emergence of three novel GII.4 clusters (GII.4 San Francisco, GII.4 Allegany and GII.4 Wichita). GII.4 Sydney was identified with 4 P-types (P4, P12, P16, and P31). GII.4 San Francisco and GII.4 Allegany had a P31 RdRp, whereas GII.4 Wichita strains had P4. GII.4 Allegany and GII.4 Wichita exhibited major amino acid substitutions in epitopes A-E, G, and H, while GII.4 San Francisco viruses have an alanine insertion in epitope A. Both GII.4 Allegany and GII.4 Wichita VLPs bound porcine gastric mucin at a similar level as GII.4 New Orleans and GII.4 Sydney. However, blocking of binding to VLPs by human serum pools demonstrated their antigenicity was significantly different. CONCLUSION: We identified three new emerging GII.4 noroviruses co-circulating with GII.4 Sydney. Early detection of new strains will aid in tracking their spread and assessing their pandemic potential. |
Ongoing symptoms after acute SARS-CoV-2 or influenza infection in a case-ascertained household transmission study: 7 US Sites, 2021-2023
Bullock A , Dalton AF , Stockwell MS , McLaren SH , Sano E , Nguyen HQ , Rao S , Asturias E , Lutrick K , Ellingson KD , Maldonado Y , Mellis AM , Smith-Jeffcoat SE , Grijalva CG , Talbot HK , Rolfes MAR , Biddle JE , Zhu Y , Ledezma K , Pryor K , Valdez de Romero A , Vargas C , Petrie JG , Floris-Moore M , Bowman N . Clin Infect Dis 2025 ![]() ![]() ![]() BACKGROUND: The prevalence and risk factors for ongoing symptoms following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [SCV2]) or influenza infection are not well characterized. We conducted a prospective cohort study of households wherein ≥1 individual was infected with SCV2 or influenza to evaluate prevalence of and factors associated with ongoing symptoms at 90 days. METHODS: Index cases and their household contacts provided baseline health and sociodemographic information and collected daily respiratory specimens for 10 days following enrollment. Participants completed a follow-up survey 90 days after enrollment to characterize ongoing symptoms. RESULTS: We analyzed 1967 participants enrolled between December 2021 and May 2023. The risk of ongoing symptoms did not differ by infection status in SCV2 (SCV2-positive: 15.6%; SCV2-negative: 13.9%; odds ratio [OR]: 1.14; 95% CI: .7-1.69) or influenza (influenza-positive: 8.8%; influenza-negative: 10.0%; OR: .87; 95% CI: .45-1.72) households. However, among study participants with a documented infection, SCV2-positive participants had nearly twice the odds of ongoing symptoms as influenza-positive participants (OR: 1.92; 95% CI: 1.27-2.97). CONCLUSIONS: These results suggest that SCV2 households have a significantly higher prevalence of ongoing symptoms compared with influenza households (OR: 1.78; 95% CI: 1.28-2.47). Among participants with SCV2 infection, underlying conditions (adjusted OR [aOR]: 2.65; 95% CI: 1.80-3.90) and coronavirus disease 2019 (COVID-19)-like symptoms (aOR: 2.92; 95% CI: 1.15-7.43) during acute infection increased odds of ongoing symptoms at 90 days, whereas hybrid immunity reduced the odds of ongoing symptoms (aOR: 0.44; 95% CI: .22-.90). |
Addressing stigma and privacy through telemedicine: Qualitative findings on enhancing HIV care engagement among racial and ethnic minority groups
Carnes N , Koenig LJ , Wilkes AL , Gelaude D , Salabarría-Peña Y , Johnston M . J Racial Ethn Health Disparities 2025 ![]() We conducted a demonstration project of telemedicine HIV care services at the University of Florida (UF) College of Medicine, Jacksonville. Our sample focused on members of racial and ethnic minority groups living in an urban setting. As part of the project's evaluation, we conducted 13 focus groups. Focus groups assessed patient, staff, and provider experiences with facilitating or hindering factors to engaging in telemedicine. We also explored the decision-making processes among people with HIV (PWH) to engage or not in telemedicine. The 46 focus group participants included 21 PWH: 12 PWH who accepted and nine who declined participation in telemedicine. The remaining 25 focus group participants were comprised of medical, clinical support, and community-based organization staff who supported the demonstration project. An unexpected finding that emerged in the focus group narratives detailed that some PWH who accepted telemedicine visits appreciated that telemedicine minimized the stigma they have experienced during in-person healthcare encounters. Among PWH who declined a telemedicine visit, they felt the extension of service into their personal world invaded their privacy, created routes for stigma should their HIV status be disclosed outside the healthcare setting, and raised concerns about confidentiality in virtual settings. Like the PWH, the professionals were mixed in their opinions in that some felt telemedicine facilitated care while others raised concerns. Findings point to the importance of allowing PWH to select the format (in-person or via telemedicine) in which their HIV care is rendered and highlight the importance of intervening to decrease healthcare facility-based stigma. |
An updated spreadsheet tool to estimate the health and economic benefits of STI and HIV prevention activities
Chesson HW , Williams AM , Ansari B , Islam MH , Johnson BL , Collins D , Gift TL , Martin EG . Sex Transm Dis 2025 ![]() BACKGROUND: This manuscript describes an updated spreadsheet tool that sexually transmitted infection (STI) prevention programs in the United States can use to estimate the health and economic benefits of their STI and HIV prevention activities. METHODS: The development of the updated tool, STIC (Sexually Transmitted Infection Costs) Figure 2.0, involved two main components. First, we revised the tool to be more useful and user-friendly based on feedback from focus groups and usability testing. Second, we updated the mathematical model behind the calculations by (1) revising the model to reflect current STI and HIV prevention activities in the United States, (2) updating the epidemiological and economic parameters in the model using the best available evidence, and (3) including ranges (not just point estimates) in the model output. To demonstrate the use of STIC Figure 2.0, we applied it to estimate the impact of a hypothetical prevention program, consistent with that of a health department or large STI clinic in a metropolitan area. RESULTS: STIC Figure 2.0 incorporated new features, including an interactive user interface to explore findings and create customized charts for use in reports and presentations. The hypothetical example we analyzed illustrated how providing STI treatment to 2,680 people and HIV prevention services to 325 people could avert 1,253 adverse outcomes and save over $2 million in medical costs and productivity costs. CONCLUSIONS: Although subject to important limitations, STIC Figure 2.0 allows state and local programs, including STI clinics, to calculate evidence-based estimates of the impact of their program activities. |
STI clinic visits and Chlamydia/Gonorrhea testing have not returned to pre-COVID levels, five U.S. jurisdictions, 2018-2022
Diesel JC , Cope A , Pugsley R , Furness B , Rahman M , Kent JB , Dunworth A , Lee G , Davis NL . Sex Transm Dis 2025 ![]() We evaluated whether sexually transmitted infection (STI) clinic visits and chlamydia/gonorrhea tests in five jurisdictions had returned to pre-COVID levels by 2022. Patient volume and chlamydia/gonorrhea testing have not returned to pre-COVID levels, especially among people <30 years. |
Syphilis screening during pregnancy in 18- to 49-year-old women in commercially-insured claims data, 2022
Emerson B , Guoyu T , Hufstetler K , Cramer R , Pearson WS . Sex Transm Dis 2025 ![]() BACKGROUND: Syphilis cases continue to climb in the United States, with a 159% increase among women between 2018 and 2022. Congenital syphilis (CS) cases continued along the same trajectory, with a 183% increase over the same time frame. Adherence to the screening guidelines may assist in reducing this trend. Our analysis aimed to determine the proportion of commercially-insured women receiving syphilis screening during pregnancy. MATERIALS AND METHODS: We analyzed the 2022 Merative™ MarketScan® Database containing commercially-insured medical claims to determine syphilis screening rates among insured pregnant women aged 18-49 years old, insured for eight months prior to childbirth. Screening events were classified into three categories: 1st (1-13 weeks), 2nd (14-27 weeks), and 3rd (28+ weeks). Percentages and odds ratios were calculated for pregnancy categories by age category, trimester, Centers for Medicare and Medicaid Services (CMS) regions, employment, and type of health insurance. RESULTS: Of the 170,005 pregnant women in the sample, 79.6% were screened for syphilis at least once, and 95.1% resided in a state requiring syphilis testing during pregnancy. The highest percentage of pregnant women were screened during the 3rd trimester, and the majority of those screened received at least 2 tests during pregnancy. Women in states with laws had 14% greater odds for receiving any screening during pregnancy. DISCUSSION: Despite Centers for Disease Control and Prevention (CDC) syphilis screening recommendations, only 79.6% received screening among this insured population. Effective communication on the importance of syphilis screening for all medical providers and their patients may increase the screening rates and decrease the incidence of CS. |
Reports of encephalopathy among children with influenza-associated mortality - United States, 2010-11 through 2024-25 influenza seasons
Fazal A , Reinhart K , Huang S , Kniss K , Olson SM , Dugan VG , Ellington S , Budd AP , Reed C , Uyeki TM , Garg S . MMWR Morb Mortal Wkly Rep 2025 74 (6) 91-95 ![]() In late January 2025, CDC received anecdotal reports of children with influenza-associated acute necrotizing encephalopathy (ANE), a severe form of influenza-associated encephalopathy or encephalitis (IAE), including several fatal cases. In response, CDC examined trends in the proportions of cases with IAE among influenza-associated pediatric deaths reported during the 2010-11 through 2024-25 influenza seasons, including demographic and clinical characteristics of identified cases. CDC contacted state health departments to ascertain whether any pediatric influenza-associated deaths with IAE reported this season also had a diagnosis of ANE. Among 1,840 pediatric influenza-associated deaths during the 2010-11 through 2024-25 influenza seasons, 166 (9%) had IAE, ranging from 0% (2020-21 season) to 14% (2011-12 season); preliminary data for the 2024-25 season (through February 8, 2025) indicate that nine of 68 (13%) had IAE. Across seasons, the median age of patients with fatal IAE was 6 years; 54% had no underlying medical conditions, and only 20% had received influenza vaccination. Because no dedicated national surveillance for IAE or ANE exists, it is unknown if the numbers of cases this season vary from expected numbers. Health care providers should consider IAE in children with acute febrile illness and neurologic signs or symptoms lasting >24 hours. Evaluation should include testing for influenza and other viruses and neuroimaging; clinical management should include early antiviral treatment for suspected or confirmed influenza and supportive critical care management as needed. Influenza vaccination is recommended for all eligible persons aged ≥6 months as long as influenza viruses are circulating. |
Association of facility vaccination policy with influenza vaccination among healthcare personnel in acute care hospitals: national Healthcare Safety Network, 2021-22 influenza season
Huynh CT , Haanschoten E , Soe MM , Barbre K , Meng L , Edwards JR , Kalayil EJ , Lindley MC , Reses HE , Kuhar DT , Stuckey MJ , Benin A , Bell JM . Infect Control Hosp Epidemiol 2025 1-5 ![]() We examined the association between influenza vaccination policies at acute care hospitals and influenza vaccination coverage among healthcare personnel for the 2021-22 influenza season. Mandatory vaccination and masking for unvaccinated personnel were associated with increased odds of vaccination. Hospital employees had higher vaccination coverage than licensed independent practitioners. |
Interim estimates of 2024-2025 COVID-19 vaccine effectiveness among adults aged ≥18 years - VISION and IVY Networks, September 2024-January 2025
Link-Gelles R , Chickery S , Webber A , Ong TC , Rowley EAK , DeSilva MB , Dascomb K , Irving SA , Klein NP , Grannis SJ , Barron MA , Reese SE , McEvoy C , Sheffield T , Naleway AL , Zerbo O , Rogerson C , Self WH , Zhu Y , Lauring AS , Martin ET , Peltan ID , Ginde AA , Mohr NM , Gibbs KW , Hager DN , Prekker ME , Mohamed A , Johnson N , Steingrub JS , Khan A , Felzer JR , Duggal A , Wilson JG , Qadir N , Mallow C , Kwon JH , Columbus C , Vaughn IA , Safdar B , Mosier JM , Harris ES , Chappell JD , Halasa N , Johnson C , Natarajan K , Lewis NM , Ellington S , Reeves EL , DeCuir J , McMorrow M , Paden CR , Payne AB , Dawood FS , Surie D . MMWR Morb Mortal Wkly Rep 2025 74 (6) 73-82 ![]() COVID-19 vaccination averted approximately 68,000 hospitalizations during the 2023-24 respiratory season. In June 2024, CDC and the Advisory Committee on Immunization Practices (ACIP) recommended that all persons aged ≥6 months receive a 2024-2025 COVID-19 vaccine, which targets Omicron JN.1 and JN.1-derived sublineages. Interim effectiveness of 2024-2025 COVID-19 vaccines was estimated against COVID-19-associated emergency department (ED) or urgent care (UC) visits during September 2024-January 2025 among adults aged ≥18 years in one CDC-funded vaccine effectiveness (VE) network, against COVID-19-associated hospitalization in immunocompetent adults aged ≥65 years in two networks, and against COVID-19-associated hospitalization among adults aged ≥65 years with immunocompromising conditions in one network. Among adults aged ≥18 years, VE against COVID-19-associated ED/UC visits was 33% (95% CI = 28%-38%) during the first 7-119 days after vaccination. Among immunocompetent adults aged ≥65 years from two CDC networks, VE estimates against COVID-19-associated hospitalization were 45% (95% CI = 36%-53%) and 46% (95% CI = 26%-60%) during the first 7-119 days after vaccination. Among adults aged ≥65 years with immunocompromising conditions in one network, VE was 40% (95% CI = 21%-54%) during the first 7-119 days after vaccination. These findings demonstrate that vaccination with a 2024-2025 COVID-19 vaccine dose provides additional protection against COVID-19-associated ED/UC encounters and hospitalizations compared with not receiving a 2024-2025 dose and support current CDC and ACIP recommendations that all persons aged ≥6 months receive a 2024-2025 COVID-19 vaccine dose. |
Mpox in a patient with a signal transducer and activator of transcription 1 gain-of-function mutation
McHugh JW , Gomez EO , Abu-Saleh OM , Corsini Campioli CG , Chesdachai S , Nazli S , Streck NT , Cash-Goldwasser S , Rao AK , Meyer ML , Joshi AY , Boyd KP , Villalba JA , Quinton RA , Tosh PK , Shah AS . Mayo Clin Proc 2025 100 (3) 534-539 ![]() ![]() ![]() We report a case of mpox in a patient with a signal transducer and activator of transcription 1 gain-of-function mutation. Despite initial improvement with intravenous immune globulin and tecovirimat, severe symptoms developed and the patient died. This underscores the need for immune system optimization and effective virucidal treatments for mpox. |
Prevalence and determinants of viral suppression in young people living with HIV on antiretroviral therapy in southern Africa: A cross-sectional analysis of HIV survey data of 2020 and 2021
Msosa TC , Kabaghe A , Twabi HH , Mpinganjira S , Mzumara W , Sumari-De Boer M , Aarnoutse R , Wit TR , Chipungu G , Ngowi K , Kalata N , Mukoka M , Msefula C , Swai I , Zimba B , Semphere R , Makhumba G , Nliwasa M . AIDS Behav 2025 ![]() Young People Living with HIV (YPLHIV, 15-24 years) are an important demographic of Persons Living with HIV (PLHIV) globally and in Southern Africa. However, YPLHIV experience poor outcomes across the HIV diagnostic and treatment cascade due to multiple factors. We estimated the prevalence and determinants of HIV viral suppression in YPLHIV on antiretroviral therapy (ART) in selected Southern African countries. We used publicly available data from Malawi, Zimbabwe, Mozambique, Lesotho, and Eswatini collected during the Population-based HIV Impact Assessments (PHIAs) of 2020 to 2021. Weighted proportions, and 95% confidence intervals (CI) were computed to estimate the prevalence of viral suppression (< 1000c/ml) and bivariate and multivariate analyses were conducted to identify determinants of viral suppression. A total of 855 records of YPLHIV on ART were included in the analysis. The prevalence of viral suppression in YPLHIV on ART was 82.4% (95% CI: 76.7, 86.9). Residing in Mozambique and duration on ART were inversely associated with viral suppression; adjusted odds ratios (AORs) of 0.37 (95% CI: 0.14, 0.95), and 0.87 (95% CI: 0.80, 0.94), respectively. A negative result in the depression screen, being married/cohabitating, and ever switching an ART regimen were positively associated with viral suppression: AORs of 5.78 (95% CI: 2.21, 15.11), 3.72 (95% CI: 1.44, 9.63), and 3.44 (95% CI: 1.69, 7), respectively. YPLHIV had suboptimal viral suppression lower than the UNAIDS 95% targets and may benefit from further research and tailored interventions addressing modifiable factors associated with viral suppression such as depression. |
Broadly neutralizing antibodies targeting pandemic GII.4 variants or seven GII genotypes of human norovirus
Park J , Lindesmith LC , Olia AS , Costantini VP , Brewer-Jensen PD , Mallory ML , Kelley CE , Satterwhite E , Longo V , Tsybovsky Y , Stephens T , Marchioni J , Martins CA , Huang Y , Chaudhary R , Zweigart M , May SR , Reyes Y , Flitter B , Vinjé J , Tucker SN , Ippolito GC , Lavinder JJ , Snijder J , Kwong PD , Georgiou G , Baric RS . Sci Transl Med 2025 17 (788) eads8214 ![]() ![]() ![]() Human norovirus causes more than 700 million illnesses annually. Extensive genetic diversity and a paucity of information on conserved neutralizing epitopes pose major obstacles to the design of broadly protective norovirus immunogens. Here, we used high-resolution liquid chromatography-tandem mass spectrometry (LC-MS/MS)-driven proteomics to quantitatively characterize the circulating serum IgG repertoire before and after immunization with an experimental monovalent norovirus GII.4 VP1 capsid-encoding adenoviral vaccine. Two participants were specifically selected on the basis of the breadth of serum neutralization responses either across GII.4 variants (participant A) or across GII genotypes (participant B). In participant A, vaccination back-boosted highly abundant serum antibody clonotypes targeting epitopes conserved among rapidly evolving GII.4 variants spanning from a strain identified in 1987 to a strain identified in 2019. In participant B, we identified a recall response consisting of broadly neutralizing monoclonal antibodies with remarkable cross-GII ligand-binding blockade (blocking ≥ seven GII genotypes) and virus neutralization breadth. The cocrystal structure of one of these antibodies, VX22, in complex with the VP1 capsid protruding (P) domain revealed a highly conserved epitope (residues 479 to 484 and 509 to 513) within two lateral loops of the P1 subdomain. Antibody evolutionary trajectory analysis further revealed that VX22 had originally evolved from an early heterologous infection, likely by a GII.12 strain. Together, our study demonstrates that norovirus human monoclonal antibodies with broad GII.4 potency and cross-GII breadth can be boosted in serum after immunization with an adenoviral vector-based vaccine, findings that may guide the design of immunogens for broadly protective norovirus vaccines. |
HIV clusters reported by state and local health departments in the United States, 2020-2022
Philpott DC , Curran KG , Russell OO , McClung RP , Hallmark CJ , Pieczykolan LL , Schlanger K , Panneer N , Oster AM , France AM . J Acquir Immune Defic Syndr 2025 ![]() ![]() ![]() BACKGROUND: Clusters of rapid HIV transmission indicate larger underlying networks that are not effectively reached by HIV prevention, testing, and care services. Starting in 2018, the Centers for Disease Control and Prevention (CDC) funded 59 U.S. health departments (HDs) to detect and respond to HIV clusters; HDs began reporting clusters to CDC in January 2020. METHODS: For clusters reported to CDC, we described cluster characteristics at detection, including detection method; size; HIV transmission category, defined as that of >50% of cluster members; and HD investigation and response activities. RESULTS: During 2020-2022, 45 HDs reported 322 HIV clusters, with most detected by molecular analysis of HIV sequences (75%). Most were detected in the South (46%) and three-quarters were predominant sexual transmission. Median cluster size at detection for molecular clusters was 10 persons (interquartile range 7-18). Among 205 clusters with follow-up data, investigation and response activities were conducted for 95%, including direct outreach to persons in clusters for partner services (64%), medical chart reviews (42%), and focused testing events (13%). Limited data on named partners tested showed that 11% received new HIV diagnoses. CONCLUSIONS: HD HIV cluster detection activities detected many clusters. Response activities were tailored for different clusters and intervened in networks with rapid transmission and high undiagnosed infection, as indicated by high positivity among partners. Cluster detection and response is an important tool to identify and address gaps in HIV prevention, testing, and care that facilitate rapid transmission. |
The role of mortality surveillance in pandemic preparedness and response
Rao C , de Savigny D , Atuheire E , Dolan S , Munoz DC , Fat DM , Ebonwu J , Sharan M , Ofosu A , Bradshaw D , Dorrington R , Nichols E . Bull World Health Organ 2025 103 (3) 213-222 ![]() The coronavirus disease 2019 (COVID-19) pandemic exposed critical limitations in the availability of timely mortality data to inform situational assessments and guide evidence-based public health responses at local, national and global levels. Less than half of the Member States of the World Health Organization (WHO) (73 out of 194) generated the required mortality data. Member States able to meet the sudden demand for real-time data did so through strong public health leadership and strategies for coordinated data acquisition, analysis and dissemination. In most other countries, attempts were made to conduct mortality surveillance but yielded only partial data with limited utility. This experience highlighted the need for a series of strategic shifts to strengthen mortality surveillance programmes in all countries, towards complete recording of deaths and their causes with timely data dissemination. These shifts include modifying systems to enable streamlining of the compilation and use of death records from all sources while meeting the requirements of official registration processes; using electronic protocols for data management and release; and ensuring effective leadership, coordination and data use for public health action. Recently, the Africa Centres for Disease Control and Prevention developed a conceptual framework for strengthening national mortality surveillance and operational guidance for implementation. These activities and resources for improving national mortality surveillance can inform global initiatives to support pandemic preparedness and response programmes. Such initiatives will enable global readiness for early epidemic detection and disease control measure prioritization, while also building routine mortality statistics programmes for population health assessment, health policy and research. |
Model-based analysis of impact, costs, and cost-effectiveness of tuberculosis outbreak investigations, United States
Shrestha S , Cilloni L , Asay GRB , Kammerer JS , Raz K , Shaw T , Cilnis M , Wortham J , Marks SM , Dowdy D . Emerg Infect Dis 2025 31 (3) 497-506 ![]() Outbreak investigation is an essential component of tuberculosis (TB) control in the United States, but its epidemiologic impact and cost-effectiveness have not been quantified. We modeled outbreak investigation activities in the United States during 2023-2032 and estimated corresponding epidemiologic impact, economic costs (in 2022 US$), and incremental cost-effectiveness ratios from the healthcare system perspective (cost per additional quality-adjusted life-year gained). We projected that outbreak investigations would result in 1,030,000 (95% uncertainty interval [UI] 376,000-1,740,000) contacts investigated, leading to 4,130 (95% UI 1,420-7,640) TB diagnoses and 104,000 (95% UI 37,600-181,000) latent TB infection diagnoses, at a total cost of US $219 million (95% UI $80-$387 million). We estimated that 5,560 (95% UI 1,720-11,400) TB cases would be averted through early detection and treatment, and the incremental cost-effectiveness of outbreak investigations, compared with no outbreak investigations, was $27,800 per quality-adjusted life-year gained (95% UI $4,580-$68,700). |
Effects of the COVID-19 pandemic on TB outcomes in the United States: A Bayesian analysis
Swartwood NA , Cohen T , Marks SM , Hill AN , Beeler Asay GR , Self J , Feng PI , Horsburgh CR Jr , Salomon JA , Menzies NA . Clin Infect Dis 2025 ![]() BACKGROUND: Tuberculosis (TB) notifications and deaths in the United States fluctuated substantially during the COVID-19 pandemic. We analyzed multiple data sources to understand the factors contributing to these changes and estimated future TB trends. METHODS: We identified four mechanisms potentially contributing to observed TB trends during 2020-2023: immigration, respiratory contact rates, rates of accurate diagnosis and treatment initiation, and mortality rates for persons experiencing TB disease. We employed a Bayesian approach to synthesize evidence on how these mechanisms changed during the pandemic and how they might have combined to produce observed 2020-2023 TB data, using a transmission-dynamic model to link mechanisms to TB outcomes. We also simulated a no-pandemic-counterfactual scenario that assumed mechanisms followed pre-pandemic trends. We estimated TB outcomes associated with the pandemic until 2035 to capture lagged effects. We evaluated additional scenarios to estimate the individual effect of each mechanism. RESULTS: Over 2020-2035, we estimate an additional 2,784 (95% uncertainty interval: 2,164-3,461) TB notifications and 1,138 (1,076-1,201) TB deaths in the United States associated with changes occurring during the COVID-19 pandemic. Mechanisms had offsetting effects - decreases in TB diagnosis rates led to more TB deaths and notifications, while reductions in contact rates reduced TB deaths and notifications. Immigration changes initially reduced TB deaths, but increased deaths and notifications over time. Higher TB mortality rates increased TB deaths, but decreased TB notifications. CONCLUSIONS: While direct impacts of the COVID-19 pandemic occurred between 2020-2023, these changes may continue to influence TB incidence and mortality in future years. |
Gestational PBDE concentrations and executive function in adolescents with self- and caregiver-report: The HOME study
Cecil KM , Xu Y , Chen A , Braun JM , Sjodin A , Lanphear BP , Vuong AM , Yolton K . Environ Res 2025 273 121256 ![]() BACKGROUND: Polybrominated diphenyl ethers (PBDEs), synthetic chemicals previously used as flame retardants in commercial products, impact human behaviors, mood symptoms and cognitive abilities. OBJECTIVE: We estimated the association of gestational PBDE serum concentrations with early adolescent self- and caregiver-reported ratings of executive function in a prospective pregnancy and birth cohort. METHODS: We measured gestational serum concentrations of five PBDE congeners and created a summary exposure variable (∑(5)BDE: 28, -47, -99, -100 and -153). At age 12 years, we assessed executive function for 237 adolescents using self- and caregiver-reports with the Behavior Rating Inventory of Executive Functioning (BRIEF-2). We used multivariable linear regression models to estimate covariate-adjusted associations of lipid standardized, log(10)-transformed gestational PBDE concentrations with BRIEF-2 T-scores. We evaluated potential effect measure modification (EMM) of sex by examining sex-stratified regression models. RESULTS: As higher scores indicate greater deficits in executive function, gestational PBDE concentrations were positively associated with adolescent-reported BRIEF-2 T-scores for Global Executive Composite (BDE-28: β = 6.31 (95%CI: 2.59, 10.03), BDE-47: (β = 3.32 (95%CI: 0.1, 6.54), ∑(5)BDE: (β = 3.70 (95%CI: 0.37, 7.03), Behavior Regulation Index (BDE-28: β = 5.36 (95%CI: 1.56, 9.15), BDE-99: β = 3.53 (95%CI: 0.33, 6.74), ∑(5)BDE: β = 3.93 (95%CI: 0.57, 7.3), Emotion Regulation Index (BDE-28: β = 4.76 (95%CI: 0.88, 8.64) and the Cognitive Regulation Index (BDE-28: β = 6.69 (95%CI: 3.08, 10.31), BDE-47: β = 3.45 (95%CI: 0.3, 6.59), ∑(5)BDE: β = 3.57 (95%CI: 0.32, 6.82) and several other scales. We observed stronger associations with gestational PBDE concentrations for all congeners among males, especially for the caregiver-rated scales (all EMM p-values <0.1). DISCUSSION: This study provides evidence that gestational PBDE serum concentrations may adversely influence offspring executive function during adolescence. |
Exposure to volatile organic compounds and chronic respiratory disease mortality, a case-cohort study
Nalini M , Poustchi H , Bhandari D , Blount BC , Kenwood BM , Chang CM , Gross A , Ellison C , Khoshnia M , Pourshams A , Gail MH , Graubard BI , Dawsey SM , Kamangar F , Boffetta P , Brennan P , Abnet CC , Malekzadeh R , Freedman ND , Etemadi A . Respir Res 2025 26 (1) 88 ![]() ![]() BACKGROUND: Chronic respiratory diseases (CRDs) are the third leading cause of death worldwide. Data of the associations between specific volatile organic compounds (VOCs), a major component of air pollution and tobacco smoke, and subsequent CRD mortality in the general population are scarce. METHODS: In a case-cohort analysis within the population-based Golestan cohort study (n = 50045, aged 40-75 years, 58% women, enrollment: 2004-2008, northeastern Iran), we included all participants who died from CRD during follow-up through 2018 (n = 242) as cases and stratified them into 16 strata defined by age, sex, residence, and tobacco smoking. Subcohort participants (n = 610) were randomly selected from all eligible cohort participants in each stratum, and sampling fractions were calculated. Baseline urine samples were used to measure 20 VOCs using ultra high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. After excluding participants with previous history of CRDs, we used stratified Cox regression models weighted by the inverse sampling fractions (i.e. inverse probability weighting) adjusted for potential confounders, including urinary cotinine and pack-years of smoking, to calculate hazard ratios (HR) for the associations between biomarker tertiles and CRD mortality. RESULTS: Data from 545 non-case, sub-cohort participants and 149 cases (69.1% chronic obstructive pulmonary disease, 13.4% asthma, 17.5% other CRDs) were assessed in this study. During a follow-up of 10.5 years, associations [2nd and 3rd vs. 1st tertiles, HR (95% confidence interval), p for trend] were observed between metabolites of acrolein [1.56 (0.64,3.79), 3.53 (1.53,8.16), 0.002] and styrene/ethylbenzene [1.17 (0.53,2.60), 3.24 (1.37,7.66), 0.005] and CRD mortality, which persisted after excluding the first four years of follow-up. CONCLUSION: Our findings support prior research suggesting respiratory toxicity of VOCs. Further investigation and monitoring of these compounds, especially acrolein and styrene/ethylbenzene, as CRD risk factors, are recommended. |
Assessing the utility of healthcare claims data to determine potential health impacts of PFAS exposure with public drinking water
Namulanda G , Condon S , Palmer TL , Ellis E , Yip F , Reh CM , Breysse P . Environ Epidemiol 2025 9 (2) e368 ![]() Healthcare claims data can support the timely surveillance of health outcomes from exposures to emerging and established environmental contaminants such as per- and polyfluoroalkyl substances (PFAS). PFAS are widely used in a variety of consumer products and industrial applications. They are detected in almost all Americans. PFAS exposure has been associated with several health outcomes including high cholesterol and thyroid disease. In 2014, PFAS were detected in five drinking water wells in New Castle City, New Castle County, Delaware. Perfluorooctane sulfonate and perfluorooctanoic acid were measured above the then Environmental Protection Agency's lifetime health advisory of 70 parts per trillion. This study uses healthcare claims data to show that healthcare plan members living in the ZIP code served by the five wells were at higher risk for type 2 diabetes, hypertension, hypertensive diseases, coronary artery disease, and hyperthyroidism based on new claims compared with healthcare plan members living elsewhere in the county. Healthcare claims data provided timely information on health outcomes not captured by traditional public health surveillance systems and at finer geographic levels. |
Mechanistic models are hypotheses: A perspective
Glasser JW , Feng Z . Math Biosci 2025 109419 ![]() Science involves perceiving patterns (events that are repeated) in observations, hypothesizing causal explanations (underlying processes), and testing them. Mathematical models either describe or provide explanations for patterns. The equations of descriptive models have convenient mathematical properties while those of mechanistic ones correspond to processes. The parameters of descriptive models are fitted to observations by choosing values that minimize discrepant predictions. Because mechanistic models are hypotheses about the processes underlying patterns, their parameters should not be fitted, but rather, based insofar as possible on first principles or estimated independently. The precision of mathematics facilitates comparing the predictions of mechanistic models to the patterns that they purport to explain and, until concordant, identifying and remedying the cause(s) of disparities. The findings and conclusions in this report are those of the authors and do not necessarily represent the official positions of the Centers for Disease Control and Prevention or National Science Foundation. |
Exploring associations of financial well-being with health behaviours and physical and mental health: a cross-sectional study among US adults
Mercado C , Bullard KM , Bolduc MLF , Banks D , Andrews C , Freggens ZRF , Njai R . BMJ Public Health 2024 2 (1) e000720 ![]() BACKGROUND: Health disparities exist across socioeconomic status levels, yet empirical evidence between financial well-being (FWB) and health are limited. METHODS: This cross-sectional study combined data from 25 370 adults aged ≥18 years in the 2019 National Health Interview Survey with estimated household FWB scores from the Consumer Financial Protection Bureau's 2016 National Financial Well-being Survey. FWB associations with health service visits, biometric screenings, smoking status, body mass index and physical and mental conditions were tested using age-adjusted, sex-adjusted and health insurance coverage-adjusted linear regression analysis. RESULTS: In 2019, the mean FWB for US adults was 56.1 (range 14 (worse) to 95 (best)). With increasing time since the last health service visit or screening, FWB was increasingly lower compared with adults with visits or screenings <1 year (≥10 years or 'never', FWB ranged from -1 (blood sugar check) to -6.5 (dental examination/cleaning) points). FWB was lower with declining general health status (excellent (reference), very good (-0.5 points), good (-3.4 points) and fair/poor (-6.6 points)). Adults with physical health conditions had FWB lower than adults without (range -0.4 (high cholesterol) to -4.6 (disability) points). FWB were lower in adults who have ever been diagnosed with anxiety disorder (-1.8 points) or depression (-2 points). Adults managing their anxiety or depression (no/minimal symptoms currently) had greater FWB (anxiety: 3 points and depression: 4.1 points) than those with symptoms. CONCLUSION: Given the observed associations between FWB and health-related measures, it is crucial to consider FWB in primary and secondary health prevention efforts, recognising the relationship between economics, health and wellness. |
Recent use of novel data streams during foodborne illness cluster investigations by the United States Food and Drug Administration: Qualitative review
Bazaco MC , Carstens CK , Greenlee T , Blessington T , Pereira E , Seelman S , Ivory S , Jemaneh T , Kirchner M , Crosby A , Viazis S , van Twuyver S , Gwathmey M , Malais T , Ou O , Kenez S , Nolan N , Karasick A , Punzalan C , Schwensohn C , Gieraltowski L , Chen Parker C , Jenkins E , Harris S . JMIR Public Health Surveill 2025 11 e58797 ![]() ![]() ![]() Foodborne illness is a continuous public health risk. The recognition of signals indicating a cluster of foodborne illness is key to the detection, mitigation, and prevention of foodborne adverse event incidents and outbreaks. With increased internet availability and access, novel data streams (NDSs) for foodborne illness reports initiated by users outside of the traditional public health framework have emerged. These include, but are not limited to, social media websites, web-based product reviews posted to retailer websites, and private companies that host public-generated notices of foodborne illnesses. Information gathered by these platforms can help identify early signals of foodborne illness clusters or help inform ongoing public health investigations. Here we present an overview of NDSs and 3 investigations of foodborne illness incidents by the US Food and Drug Administration that included the use of NDSs at various stages. Each example demonstrates how these data were collected, integrated into traditional data sources, and used to inform the investigation. NDSs present a unique opportunity for public health agencies to identify clusters that may not have been identified otherwise, due to new or unique etiologies, as shown in the 3 examples. Clusters may also be identified earlier than they would have been through traditional sources. NDSs can further provide investigators supplemental information that may help confirm or rule out a source of illness. However, data collected from NDSs are often incomplete and lack critical details for investigators, such as product information (eg, lot numbers), clinical or medical details (eg, laboratory results of affected individuals), and contact information for report follow-up. In the future, public health agencies may wish to standardize an approach to maximize the potential of NDSs to catalyze and supplement adverse event investigations. Additionally, the collection of essential data elements by NDS platforms and data-sharing processes with public health agencies may aid in the investigation of foodborne illness clusters and inform subsequent public health and regulatory actions. |
Strong herd effects of human papillomavirus vaccination
Chesson HW , Markowitz LE . J Infect Dis 2025 ![]() ![]() ![]() |
Interim estimates of 2024-2025 seasonal influenza vaccine effectiveness - four vaccine effectiveness networks, United States, October 2024-February 2025
Frutos AM , Cleary S , Reeves EL , Ahmad HM , Price AM , Self WH , Zhu Y , Safdar B , Peltan ID , Gibbs KW , Exline MC , Lauring AS , Ball SW , DeSilva M , Tartof SY , Dascomb K , Irving SA , Klein NP , Dixon BE , Ong TC , Vaughn IA , House SL , Faryar KA , Nowalk MP , Gaglani M , Wernli KJ , Murugan V , Williams OL , Selvarangan R , Weinberg GA , Staat MA , Halasa NB , Sahni LC , Michaels MG , Englund JA , Kirby MK , Surie D , Dawood FS , Clopper BR , Moline HL , Link-Gelles R , Payne AB , Harker E , Wielgosz K , Weber ZA , Yang DH , Lewis NM , DeCuir J , Olson SM , Chung JR , Flannery B , Grohskopf LA , Reed C , Garg S , Ellington S . MMWR Morb Mortal Wkly Rep 2025 74 (6) 83-90 ![]() Annual influenza vaccination is recommended for all persons aged ≥6 months in the United States. Interim influenza vaccine effectiveness (VE) was calculated among patients with acute respiratory illness-associated outpatient visits and hospitalizations from four VE networks during the 2024-25 influenza season (October 2024-February 2025). Among children and adolescents aged <18 years, VE against any influenza was 32%, 59%, and 60% in the outpatient setting in three networks, and against influenza-associated hospitalization was 63% and 78% in two networks. Among adults aged ≥18 years, VE in the outpatient setting was 36% and 54% in two networks and was 41% and 55% against hospitalization in two networks. Preliminary estimates indicate that receipt of the 2024-2025 influenza vaccine reduced the likelihood of medically attended influenza and influenza-associated hospitalization. CDC recommends annual receipt of an age-appropriate influenza vaccine by all eligible persons aged ≥6 months as long as influenza viruses continue to circulate locally. |
Trends in cervical precancers identified through population-based surveillance - human papillomavirus vaccine impact monitoring project, five sites, United States, 2008-2022
Gargano JW , Stefanos R , Dahl RM , Castilho JL , Bostick EA , Niccolai LM , Park IU , Blankenship S , Brackney MM , Chan K , Delikat EL , Ehlers S , Barrera KG , Kurtz R , Meek JI , Whitney E , Vigar M , Unger ER , Markowitz LE . MMWR Morb Mortal Wkly Rep 2025 74 (6) 96-101 ![]() In 2006, human papillomavirus (HPV) vaccine was first recommended in the United States to prevent cancers and other diseases caused by HPV; vaccination coverage increased steadily through 2021, and increasing numbers of young women had received HPV vaccine as children or adolescents. Since 2008, CDC has monitored incidence of precancerous lesions (cervical intraepithelial neoplasia [CIN] grades 2-3 and adenocarcinoma in situ [AIS], collectively CIN2+), which are detected through cervical cancer screening and can be used as an intermediate outcome for monitoring vaccination impact, via the five-site Human Papillomavirus Vaccine Impact Monitoring Project. This analysis describes trends in incidence of CIN2+ and CIN3+ (i.e., CIN grade 3 and AIS) lesions during 2008-2022. Among women aged 20-24 years who were screened for cervical cancer, rates during 2008-2022 decreased for CIN2+ by 79%, and for CIN3+ by 80%. In the same period, CIN3+ rates among screened women aged 25-29 years decreased by 37%. These data are consistent with considerable impact of HPV vaccination for preventing cervical precancers among women in the age groups most likely to have been vaccinated, and support existing recommendations to vaccinate children at the routinely recommended ages as a cancer prevention measure. |
Implementing SARS-CoV-2 routine surveillance in antenatal care in Zambia, 2021-2022: best practices and lessons learned
Tembo T , Heilmann E , Kabamba BM , Fwoloshi S , Kalenga K , Chilambe F , Siwinga M , Rutagwera MR , Musunse M , Kangale C , Yingst S , Yadav R , Savory T , Gutman JR , Sikazwe I , Mulenga LB , Moore CB , Hines JZ . BMC Public Health 2025 25 (1) 813 ![]() ![]() ![]() BACKGROUND: In Zambia, the true extent of SARS-CoV-2 infections is unknown because initial surveillance focused on patients with symptoms or severe disease. Antenatal sentinel surveillance had not been used to assess infection trends. The ANC COVID-19 surveillance study sought to determine SARS-CoV-2 seroprevalence and COVID-19 vaccine uptake among pregnant women. We provide insight into the study implementation, challenges encountered, best practices, and lessons learned. METHODS: A repeated cross-sectional seroprevalence survey was implemented at 39 health facilities in four districts from September 2021 to September 2022. Pregnant women aged 15-49 years were enrolled at their first antenatal care visits. An electronic questionnaire gathered demographics and other COVID-19 related information from consenting participants. A dried blood sample was collected to detect IgG antibodies using a multiplex bead assay. Seropositive results were categorized as infection, infection and vaccination or infection based on anti-RBD and anti-nucleocapsid test results. Problems and their root causes were identified as they occurred. Practical problem-solving strategies were devised, implemented, and monitored to ensure that goals were accomplished. RESULTS: In the primary analysis, 7% of the 9,221 samples collected from participants were not tested because they were missing. COVID-19 vaccine uptake of 9,111 pregnant women was assessed. Approximately 64% of participants were cumulatively seropositive for SARS-CoV-2 antibodies. Seroprevalence increased from 27.8% in September 2021 to 56.6% in July 2022. We observed an increase in vaccine coverage (0.5-27%) over time. Women aged 40-49 years old, without education and with prior COVID-19 infection were associated with higher vaccine uptake. The Delta variant of COVID-19 and the reallocation of health facilities between two partners delayed surveillance activities and increased the cost of implementation (e.g., the purchase of additional calibration and validation kits and DBS cards). Protocol deviations were attributed to the lack of experience in conducting research but, the district RAs repeatedly trained health facility staff to enhance their research knowledge. CONCLUSIONS: Incorporating SARS-CoV-2 surveillance into routine antenatal care is feasible and potentially sustainable when existing health system infrastructure, human resources, and surveillance systems are leveraged. Yet, careful planning is needed to anticipate implementation challenges and ensure high-quality data collection. |
Use and characteristics of clinical coding for post-COVID conditions in a retrospective US cohort
Ford ND , Baca S , Dalton AF , Koumans EH , Raykin J , Patel PR , Saydah S . J Public Health Manag Pract 2025 ![]() CONTEXT: Little is known about when and how the ICD-10-CM diagnosis code for Post-COVID Conditions (PCC; U09.9) is being used to document PCC. OBJECTIVES: To examine the use and characteristics of clinical coding for PCC. DESIGN: A retrospective cohort. SETTING: Transaction-level medical encounters, laboratory testing results, pharmacy claims, and medical claims for inpatient and outpatient care from the HealthVerity database. PARTICIPANTS: 382 400 US adults and children with private health insurance, Medicare, and Medicaid who had U09.9 code documented during October 1, 2021-June 30, 2023. OUTCOME MEASURES: Count of first use of the U09.9 code, (a) overall, over time, and proportion by provider type; (b) prevalence of PCC-associated incident conditions co-documented with U09.9; (c) number of documented SARS-CoV-2 infections preceding U09.9; (d) timing between infection and U09.9; (e) encounters during the 6 months following first use of U09.9. RESULTS: Overall, 0.6% of 65 556 068 patients had a PCC diagnosis code (64.6% female; 6 in 10 had ≥1 preexisting conditions). The highest count of new U09.9 codes occurred during Quarter 1 and Quarter 3 of 2022 and was documented by a variety of provider specialties. The most prevalent co-documented PCC-associated incident conditions were respiratory (13.4%) and malaise and fatigue (7.8%). Only 62% of patients had SARS-CoV-2 infection documented preceding U09.9; median time to PCC documentation was 17.0 days (interquartile range [IQR] = 5.0, 61.0). Patients with ≥1 encounters during which PCC was documented in the 6 months following their index encounter (n = 109 794) had, on average, 25.5 additional encounters (median = 14 [IQR = 7, 29]). CONCLUSIONS: Our study describes the sociodemographic characteristics, complex clinical manifestations, and high healthcare use of patients following a PCC diagnosis. These findings may inform efforts to identify and treat PCC, inform healthcare planning, and support efforts to educate clinicians about the definition of PCC and accurate application of the code. |
Machine learning and natural language processing to improve classification of atrial septal defects in electronic health records
Guo Y , Shi H , Book WM , Ivey LC , Rodriguez FH 3rd , Sameni R , Raskind-Hood C , Robichaux C , Downing KF , Sarker A . Birth Defects Res 2025 117 (3) e2451 ![]() ![]() BACKGROUND: International Classification of Disease (ICD) codes can accurately identify patients with certain congenital heart defects (CHDs). In ICD-defined CHD data sets, the code for secundum atrial septal defect (ASD) is the most common, but it has a low positive predictive value for CHD, potentially resulting in the drawing of erroneous conclusions from such data sets. Methods with reduced false positive rates for CHD among individuals captured with the ASD ICD code are needed for public health surveillance. METHODS: We propose a two-level classification system, which includes a CHD and an ASD classification model, to categorize cases with an ASD ICD code into three groups: ASD, other CHD, or no CHD (including patent foramen ovale). In the proposed approach, a machine learning model that leverages structured data is combined with a text classification system. We compare performances for three text classification strategies: support vector machines (SVMs) using text-based features, a robustly optimized Transformer-based model (RoBERTa), and a scalable tree boosting system using non-text-based features (XGBoost). RESULTS: Using SVM for both CHD and ASD resulted in the best performance for the ASD and no CHD group, achieving F(1) scores of 0.53 (±0.05) and 0.78 (±0.02), respectively. XGBoost for CHD and SVM for ASD classification performed best for the other CHD group (F(1) score: 0.39 [±0.03]). CONCLUSIONS: This study demonstrates that it is feasible to use patients' clinical notes and machine learning to perform more fine-grained classification compared to ICD codes, particularly with higher PPV for CHD. The proposed approach can improve CHD surveillance. |
Assessment of health conditions from patient electronic health record portals vs self-reported questionnaires: an analysis of the INSPIRE study
Khera R , Sawano M , Warner F , Coppi A , Pedroso AF , Spatz ES , Yu H , Gottlieb M , Saydah S , Stephens KA , Rising KL , Elmore JG , Hill MJ , Idris AH , Montoy JCC , O'Laughlin KN , Weinstein RA , Venkatesh A . J Am Med Inform Assoc 2025 ![]() OBJECTIVES: Direct electronic access to multiple electronic health record (EHR) systems through patient portals offers a novel avenue for decentralized research. Given the critical value of patient characterization, we sought to compare computable evaluation of health conditions from patient-portal EHR against the traditional self-report. MATERIALS AND METHODS: In the nationwide Innovative Support for Patients with SARS-CoV-2 Infections Registry (INSPIRE) study, which linked self-reported questionnaires with multiplatform patient-portal EHR data, we compared self-reported health conditions across different clinical domains against computable definitions based on diagnosis codes, medications, vital signs, and laboratory testing. We assessed their concordance using Cohen's Kappa and the prognostic significance of differentially captured features as predictors of 1-year all-cause hospitalization risk. RESULTS: Among 1683 participants (mean age 41 ± 15 years, 67% female, 63% non-Hispanic Whites), the prevalence of conditions varied substantially between EHR and self-report (-13.2% to +11.6% across definitions). Compared with comprehensive EHR phenotypes, self-report under-captured all conditions, including hypertension (27.9% vs 16.2%), diabetes (10.1% vs 6.2%), and heart disease (8.5% vs 4.3%). However, diagnosis codes alone were insufficient. The risk for 1-year hospitalization was better defined by the same features from patient-portal EHR (area under the receiver operating curve [AUROC] 0.79) than from self-report (AUROC 0.68). DISCUSSION: EHR-derived computable phenotypes identified a higher prevalence of comorbidities than self-report, with prognostic value of additionally identified features. However, definitions based solely on diagnosis codes often undercaptured self-reported conditions, suggesting a role of broader EHR elements. CONCLUSION: In this nationwide study, patient-portal-derived EHR data enabled extensive capture of patient characteristics across multiple EHR platforms, allowing better disease phenotyping compared with self-report. |
Older adult fall injuries and the usage of fall screener tools
Dobash DS , Kakara RS . J Saf Res 2025 93 177-184 ![]() Introduction: Older adult (≥65 years) falls are common and may result in severe injuries. There is limited knowledge about what proportion of older adults who fall sustain injuries that need medical attention. Screening is the first step in helping older adults reduce their risk of falls. However, there is limited research on how well current fall screeners can predict fall injuries. Methods: Previously collected data from community-dwelling older adults enrolled in a 13-month long study, from the AmeriSpeak Panel, were analyzed. Baseline survey included questions related to demographics, falls risk factors, and falls risk screeners (CDC's 3 Key Questions (3KQ) and Stay Independent). Weighted percentages and 95% confidence intervals (CI) of older adults reporting one or more falls, fall-related injuries, falls needing any medical attention, falls resulting in doctor visits, and falls resulting in Emergency Department (ED) visits and/or hospitalization by demographics and fall risk factors were calculated. Risk ratios, sensitivity, specificity, and positive and negative predictive values were calculated to compare the two screeners’ ability to predict fall injury outcomes. Results: Among older adults who fell, 24.8% had an injury resulting in any medical attention, 14.5% sought treatment at a doctor's office, and 14.3% sought treatment at an ED/hospital. Sensitivity estimates for baseline 3KQ and Stay Independent screeners for falls resulting in an ED/hospital visit were 87.3% and 75.0%, respectively. Specificity estimates were 47.4% and 63.6%. Conclusion: At least one in four older adults who fell needed medical attention. The 3KQ or Stay Independent screeners identified a large proportion of older adults who sought treatment at an ED/hospital for falls. However, using them may result in a large number of false positives. Practical Application: Clinicians may use these screeners to identify older adults at high fall injury risk, assess them for specific risk factors, and intervene accordingly. © 2025 National Safety Council and Elsevier Ltd |
Emergence and spread of clostridioides difficile isolates with reduced fidaxomicin susceptibility in an acute care hospital
Redmond SN , Cadnum JL , Jencson AL , Kaple CE , Wilson BM , Skinner AM , Gargis AS , Hwang M , Choi H , Chatterjee P , Jinadatha C , Donskey CJ . Clin Infect Dis 2025 ![]() ![]() BACKGROUND: There have been several recent reports of Clostridioides difficile infection (CDI) due to isolates with reduced fidaxomicin susceptibility (minimum inhibitory concentration [MIC] ≥ 2 µg/mL). However, the clinical implications are uncertain because fidaxomicin achieves high concentrations in the intestinal tract. METHODS: In an acute care hospital, we conducted a 3-year cohort study of patients with CDI to determine the frequency of infection with isolates with reduced fidaxomicin susceptibility and the impact on response to fidaxomicin treatment. Stool specimens were cultured for C. difficile, and susceptibility testing was performed using agar dilution. Whole-genome sequencing was used to identify mutations associated with reduced fidaxomicin susceptibility and to determine relatedness of isolates. For genomically related susceptible and reduced susceptibility isolates from the same patient, we compared rates of growth, sporulation, and toxin production. RESULTS: Of 108 fidaxomicin-treated patients, 6 (5.6%) were infected with isolates that possessed reduced fidaxomicin susceptibility (MICs 8-32 µg/mL), including 3 with initially susceptible isolates followed by clinical failure with subsequent recovery of genomically related isolates with reduced susceptibility. Isolates with reduced fidaxomicin susceptibility harbored mutations in RNA polymerase associated with reduced susceptibility and exhibited reduced toxin production, and 20% to 40% of isolates tested had reduced growth and/or sporulation in comparison with susceptible isolates. Three patients were infected with genomically indistinguishable ribotype 097 isolates with reduced fidaxomicin susceptibility. CONCLUSIONS: Our findings highlight the potential for the emergence on therapy of clinically relevant reduced fidaxomicin susceptibility in C. difficile and its spread via transmission to other patients. |
Parent-teen concordance of selected adverse childhood experiences in a national sample of teenagers: Findings from National Health Interview Survey - Teen
Ng AE , Swedo E , Zablotsky B , Black LI , Niolon PH , Bose J , Blumberg SJ . Child Abuse Negl 2025 163 107339 ![]() BACKGROUND: Parent-reported surveys are commonly used in child health research. However, few national surveys have examined concordance between parent- and teen-reported Adverse Childhood Experiences (ACEs). OBJECTIVE: To examine concordance between parent- and teen-reported ACEs among a nationally representative sample of teens and understand sociodemographic correlates of concordance. PARTICIPANTS AND SETTING: Data were collected as part of the National Health Interview Survey (NHIS), an annual nationally representative survey of the United States, with parent-reported interviews and its follow-back survey, the National Health Interview Survey-Teen (NHIS-Teen), a self-administered web survey of youth aged 12-17 years. METHODS: Parent- and teen-reported ACEs, and several measures of concordance (e.g. weighted Cohen's kappa, prevalence adjusted bias adjusted kappa (PABAK)) are presented. Unadjusted logistic regressions tested associations between sociodemographic characteristics and likelihood of concordance for each ACE. RESULTS: ACEs prevalence based on parent report were lower compared to teen report (e.g. victim of or witnessed violence in the neighborhood, 6.5 % parent-reported vs. 15.5 %, teen-reported). Weighted Cohen's kappa statistics showed fair to moderate agreement (ks ranging from 0.27 to 0.53), with PABAK statistics showing slightly higher levels (ks ranging from 0.41 to 0.88). CONCLUSIONS: There is discordance in ACEs reporting between teens and their parents, with parents less likely to report that their teen experience an ACE than teens are. This emphasizes the importance of collecting information directly from teenagers, which may help inform intervention work. |
Psychosocial risks and ethical implications of technology: considerations for decent work
Schulte PA , Streit JMK . Ann Work Expo Health 2025 ![]() Decent work, a United Nations Sustainable Development Goal, is built on the ethical treatment of workers and ensures respect of their security, freedom, equity, and dignity. In the future, a wide range of technological forces may pose significant impediments to the availability and quality of decent work. This paper applies a prescriptive taxonomy to categorize evidence of the psychosocial impacts technology may bring to the future of work and elucidate the associated ethical concerns. Ethical objectives in support of a future defined by decent work are also offered. Central to this technoethical discourse are the principles of nonmaleficence, beneficence, autonomy, justice, and respect for persons. Expanded technoethical education, ethical technology assessments, ethical foresight analysis, and revised ethical standards are important ways to address technology-related ethical challenges on a larger scale. The findings in this paper may serve as a foundation for the systemic prevention and control of adverse effects and ethical concerns from the use of technology in the workplace of the future. |
Evaluation of passive silicone samplers compared to active sampling methods for polycyclic aromatic hydrocarbons during fire training
Sen P , Calkins M , Stakes K , Neumann DL , Chen IC , Horn GP . Toxics 2025 13 (2) 132 ![]() Firefighters are occupationally exposed to many chemicals, including polycyclic aromatic hydrocarbons (PAHs), which are formed by the incomplete combustion of organic matter during fire response and training activities. However, due to the harsh environments in which firefighters work, as well as consideration for time and physical safety while wearing bulky equipment, traditional active sampling methods may not be feasible to measure PAH exposures. Silicone passive samplers offer an alternative approach to assess exposure during fire responses and live fire training due to their heat resistance and ease of deployment in remote or time-limited environments. In this study, the primary objective was to investigate and determine the statistical strength of the relationship between active air sampling methods and passive silicone samplers for PAHs. In this study, silicone wristbands were paired with active sampling devices in a series of burn experiments to compare PAH measurements. Silicone-based measurements correlated strongly with active air samples for the dominant PAHs found, naphthalene and phenanthrene; however, detection was limited in the wristbands when air concentrations were low in active samples. In situations where PAH levels are expected to be high and the potential for contaminant loss via off-gassing is low, silicone samplers may be a useful tool for industrial hygienists to measure PAHs in fire and other emergency responses in extreme environments. |
Improving battery design for electromagnetic compatibility: A magnetic field cancellation method
Zhang Y , Zhou C , Carr J , Srednicki JR . IEEE Trans Electromagn Compat 2025 67 (1) 51-59 ![]() With the increasing demand of power and energy, more and more cells are packed into battery modules. Consequently, the electromagnetic (EM) emissions from batteries also intensify. These emissions have been observed to interfere with nearby electronic safety and health devices, causing malfunctions. While conventional methods, such as shielding, filtering, and distance separation, are commonly used to mitigate the interference issue, each has its own limitations and may not be applicable in all situations. On the other hand, magnetic field cancellation methods found in certain applications offer distinct advantages in addressing challenging magnetic field shielding or compensation issues. In this article, we introduce a novel approach to mitigate EM emissions from batteries consisting of common cylindrical form cells. The new approach leverages the coherent nature of battery cell currents when powering external load and the paired structure present in the battery pack, and then rearranges the cells so that the magnetic fields of the loops of paired cells are canceling one another. We demonstrate the validity of our approach in addressing the EM interference issue that exists in an electronic device currently used in underground coal mines. The results show a significant reduction in EM emission from the battery, highlighting the effectiveness of our approach in real applications. U.S. Government work not protected by U.S. copyright. |
Prevalence and risk factors of curable sexually transmitted and reproductive tract infections and malaria co-infection among pregnant women at antenatal care booking in Kenya, Malawi and Tanzania: a cross-sectional study of randomised controlled trial data
Gore-Langton GR , Madanitsa M , Barsosio HC , Minja DTR , Mosha J , Kavishe RA , Mtove G , Gesase S , Msemo OA , Kariuki S , Otieno K , Phiri KS , Lusingu JPA , Mukerebe C , Manjurano A , Ikigo P , Saidi Q , Onyango ED , Schmiegelow C , Dodd J , Hill J , Hansson H , Alifrangis M , Gutman J , Hunter PJ , Klein N , Ashorn U , Khalil A , Cairns M , Ter Kuile FO , Chico RM . BMJ Public Health 2024 2 (2) e000501 ![]() OBJECTIVES: Malaria and curable sexually transmitted and reproductive tract infections (STIs/RTIs) are associated with adverse pregnancy outcomes. This study reports the prevalence and risk factors of curable STIs/RTIs, STI/RTI co-infection and STI/RTI and malaria co-infection among HIV-negative pregnant women at their first antenatal care visit in Kenya, Malawi and Tanzania. METHODS: HIV-negative pregnant women of all gravidae (n=4680) were screened for syphilis with point-of-care tests and treated if positive. Separately, women provided blood samples (n=4569) for rapid plasma reagin (RPR) testing; positive cases were confirmation by Treponema pallidum particle agglutination (TPPA). Women also provided dried blood spots for batch testing of malaria by retrospective polymerase chain reaction (PCR (n=4226) methods. A randomly selected subgroup of women provided vaginal swabs for chlamydia, gonorrhoea and trichomoniasis testing by retrospective PCR batch testing (n=1431), and bacterial vaginosis diagnosis by Nugent scoring (n=1402). RESULTS: Malaria prevalence was 14.6% (95% CI 13.6 to 15.7), 45.9% (43.4 to 48.4) of women were positive for at least one curable STI/RTI and 6.7% (5.5 to 8.1) were co-infected with malaria and a curable STI/RTI. Prevalence of individual STIs/RTIs ranged from 28.5% (26.2 to 30.9) for bacterial vaginosis to 14.5% (12.7 to 16.4) for trichomoniasis, 13.8% (12.1 to 15.7) for chlamydia, 2.7% (1.9 to 3.6) for gonorrhoea and 1.7% (1.4 to 2.2) for RPR/TPPA-confirmed syphilis. The prevalence of STI/RTI co-infection was 10.1% (8.7 to 11.8). Paucigravidae, at highest risk of malaria, were also at greater risk of having chlamydia, gonorrhoea and bacterial vaginosis than multigravidae. CONCLUSIONS: Of women infected with malaria, 49.0% also had a curable STI/RTI and one in five women with at least one STI/RTI were co-infected with more than one STI/RTI. Current antenatal interventions that address malaria and curable STIs/RTIs remain suboptimal. New approaches to preventing and managing these infections in pregnancy are urgently needed. TRIAL REGISTRATION NUMBER: NCT03208179. |
Publisher Correction: Attractive targeted sugar baits for malaria control in western Kenya (ATSB-Kenya): enrolment characteristics of cohort children and households
Kamau A , Obiet K , Ogwang C , McDermott DP , Lesosky M , Janssen J , Odongo W , Gutman JR , Schultz JS , Nicholas W , Seda B , Chepkirui M , Aduwo F , Towett O , Otieno K , Donnelly MJ , Ochomo E , Kariuki S , Samuels AM , Ter Kuile FO , Staedke SG . Malar J 2025 24 (1) 69 ![]() |
Non-fatal opioid overdose and unmet need for medications for opioid use disorder among recently incarcerated people who inject drugs
Madera-Garcia V , Broz D , Baugher AR , Hershow RB , Dasgupta S , Asher A , Hefferon R , Worthington N , Cha S . Drug Alcohol Depend 2025 270 112634 ![]() BACKGROUND: Medications for opioid use disorder (MOUD) are key to preventing opioid overdose. Despite the high risk of opioid overdose among recently incarcerated people who use drugs, missed opportunities for engagement in MOUD treatment persist in this population. We examined the association between unmet need for MOUD and non-fatal opioid overdose among recently incarcerated people who inject drugs (PWID) and assessed prevalence of non-fatal opioid overdose by selected characteristics. METHODS: We analyzed 2022 data from the National HIV Behavioral Surveillance (NHBS) system among PWID from 20 large U.S. cities. Adjusted prevalence ratios (aPR) and 95 % confidence intervals (95 % CI) were calculated to examine the association between unmet need for MOUD and non-fatal opioid overdose. RESULTS: Among 1648 recently incarcerated PWID, 28 % reported an unmet need for MOUD and 39 % reported a non-fatal opioid-involved overdose in the past 12 months. Experiencing homelessness in the last 12 months (aPR=1.43, 95 % CI=1.27-1.61) and living in the Midwest region of the U.S. (aPR=1.18, 95 % CI=1.01-1.38) were significantly associated with reporting a non-fatal opioid overdose. Recently incarcerated PWID with an unmet need for MOUD were 1.4 times as likely to report a non-fatal opioid overdose in the past 12 months (50 %; aPR=1.42, 95 % CI=1.29-1.56) compared with recently incarcerated PWID without an unmet need for MOUD (35 %). CONCLUSIONS: Unmet need for MOUD was significantly associated with non-fatal opioid overdose among PWID who were incarcerated in the past 12 months, suggesting the need to investigate specific strategies to improve to MOUD treatment among recently incarcerated PWID. |
The mChoice App, an mHealth tool for the monitoring of preexposure prophylaxis adherence and sexual behaviors in young men who have sex with men: Usability evaluation
Dos Santos FC , Brin M , Tanner MR , Galindo CA , Schnall R . JMIR Hum Factors 2025 12 e59780 ![]() ![]() BACKGROUND: Mobile health (mHealth) apps provide easy and quick access for end users to monitor their health-related activities. Features such as medication reminders help end users adhere to their medication schedules and automatically record these actions, thereby helping manage their overall health. Due to insufficient mHealth tools tailored for HIV preventive care in young men who have sex with men (MSM), our study evaluated the usability of the mChoice app, a tool designed to enhance preexposure prophylaxis (PrEP) adherence and promote sexual health (eg, encouraging the use of condoms and being aware of the partner's HIV status and PrEP use). OBJECTIVE: This study aimed to apply systematic usability evaluations to test the mChoice app and to refine the visualizations to better capture and display patient-reported health information. METHODS: Usability testing involved heuristic evaluations conducted with 5 experts in informatics and user testing with 20 young MSM who were taking or were eligible to take PrEP. RESULTS: End users demonstrated satisfaction with the appearance of the mChoice app, reporting that the app has an intuitive interface to track PrEP adherence. However, participants highlighted areas needing improvement, including chart titles and the inclusion of "undo" and "edit" buttons to improve user control when recording PrEP use. CONCLUSIONS: Usability evaluations involving heuristic experts and end users provided valuable insights into the mChoice app's design. Areas for improvement were identified, such as enhancing chart readability and providing additional user controls. These findings will guide iterative refinements, ensuring that future versions of the app better address the needs of its target audience and effectively support HIV prevention. |
QuickStats: Percentage distribution of deaths attributed to excessive cold or hypothermia,* by month - United States, 2023
Garnett MF . MMWR Morb Mortal Wkly Rep 2025 74 (6) 107 ![]() |
Zika virus: advancing a priority research agenda for preparedness and response
Lackritz EM , Ng LC , Marques ETA , Rabe IB , Bourne N , Staples JE , Méndez-Rico JA , Harris E , Brault AC , Ko AI , Beasley DWC , Leighton T , Wilder-Smith A , Ostrowsky JT , Mehr AJ , Ulrich AK , Velayudhan R , Golding JP , Fay PC , Cehovin A , Moua NM , Moore KA , Osterholm MT , Barrett ADT . Lancet Infect Dis 2025 ![]() ![]() ![]() The 2015-16 Zika virus epidemic emerged in the Americas and rapidly spread throughout the region and beyond, showing the epidemic potential of this mosquito-borne Orthoflavivirus and its capacity to cause severe congenital malformations and neurological sequelae. WHO declared the Zika virus epidemic a public health emergency of international concern in 2016. Despite this declaration, there are no licensed Zika virus vaccines, therapeutics, or diagnostic tests appropriate for routine antenatal screening. To address this absence of essential tools to detect and mitigate the threat of future Zika virus outbreaks, a group of global experts developed a priority agenda for Zika virus research and development. This Series paper summarises crucial challenges and knowledge gaps and outlines a comprehensive strategy to advance research, surveillance, global capacity, policy, and investment for Zika virus preparedness and response. |
Donor-derived ehrlichiosis caused by ehrlichia chaffeensis from living donor kidney transplant
Scolarici MJ , Kuehler D , Osborn R , Doyle A , Schiffman EK , Garvin A , Villalba JA , Ramos CJ , Paddock CD , Annambhotla PD , Taylor M , Salzer JS , Saddler C , Thiessen C , Kandaswamy R , Odorico J . Emerg Infect Dis 2025 31 (3) 587-590 ![]() ![]() Tickborne infections are challenging to diagnose, particularly among solid organ transplant recipients. We report a US case of donor-derived ehrlichiosis from a living kidney donation that highlights how screening for living donors may miss tickborne infections. Clinicians should consider the epidemiology of the donor when screening donations and evaluating recipients for donor-derived infection. |
Effect of prior influenza a(H1N1)pdm09 virus infection on pathogenesis and transmission of human influenza A(H5N1) clade 2.3.4.4b virus in ferret model
Sun X , Belser JA , Li ZN , Brock N , Pulit-Penaloza JA , Kieran TJ , Pappas C , Zeng H , Chang JC , Carney PJ , Bradley-Ferrell BL , Stevens J , Tumpey TM , Levine MZ , Maines TR . Emerg Infect Dis 2025 31 (3) 458-466 ![]() ![]() Reports of human infections with influenza A(H5N1) clade 2.3.4.4b viruses associated with outbreaks in dairy cows in the United States underscore the need to assess the potential cross-protection conferred by existing influenza immunity. We serologically evaluated ferrets previously infected with an influenza A(H1N1)pdm09 virus for cross-reactive antibodies and then challenged 3 months later with either highly pathogenic H5N1 clade 2.3.4.4b or low pathogenicity H7N9 virus. Our results showed that prior influenza A(H1N1)pdm09 virus infection more effectively reduced the replication and transmission of the H5N1 virus than did the H7N9 virus, a finding supported by the presence of group 1 hemagglutinin stalk and N1 neuraminidase antibodies in preimmune ferrets. Our findings suggest that prior influenza A(H1N1)pdm09 virus infection may confer some level of protection against influenza A(H5N1) clade 2.3.4.4.b virus. |
Sign up Email Alert
Content Index (Current Edition)
- Chronic Diseases and Conditions
- Communicable Diseases
- Environmental Health
- Epidemiology and Surveillance
- Food Safety
- Immunity and Immunization
- Informatics
- Injury and Violence
- Laboratory Sciences
- Maternal and Child Health
- Occupational Safety and Health
- Parasitic Diseases
- Substance Use and Abuse
- Telehealth and Telemedicine
- Vital Statistics
- Zoonotic and Vectorborne Diseases
About
CDC Science Clips is an online, continuously updated, searchable database of scientific literature published by CDC authors. Each article features an Altmetric Attention Score to track social and mainstream media mentions. If you are aware of a CDC-authored publication that does not appear in this database, please let us know.
Content Statistics
Top 5 Articles with Highest Altmetric Scores:Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. van Doremalen, N., et al. N Engl J Med 2020 382 (16) 1564-1567 |
Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. Shimabukuro, T. T., et al. N Engl J Med 2021 384 (24) 2273-2282 |
Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings - Barnstable County, Massachusetts, July 2021. Brown, C. M., et al. MMWR Morb Mortal Wkly Rep 2021 70 (31) 1059-1062 |
Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. Oster, M. E., et al. JAMA 2022 327 (4) 331-340 |
Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021. Bozio, C. H., et al. MMWR Morb Mortal Wkly Rep 2021 70 (44) 1539-1544 |
Special Topics:
Genomics and Precision Health | 6387 |
Artificial Intelligence/Machine Learning | 803 |
Advanced Molecular Detection | 1840 |
Top 5 Journals with Most Publications:
MMWR Morb Mortal Wkly Rep | 2807 |
PloS one | 1439 |
Clin Infect Dis | 1430 |
Emerg Infect Dis | 1193 |
Vaccine | 1191 |
- Page last reviewed:Feb 1, 2024
- Page last updated:Mar 10, 2025
- Content source:
- Powered by CDC PHGKB Infrastructure